closedosingdownloadefficacymoasafetytable-checktable-cross

The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

OTEZLA REDUCES TENDER AND SWOLLEN JOINTS1

Sustained reduction in tender and swollen joint count up to 4 years1,a

aPALACE 1 study. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24. Randomized patients who received ≥1 dose of study medication: OTEZLA 30 mg BID, n = 168; placebo, n = 168. The n at each time point represents the number of patients with available data at the time point.

During the placebo-controlled phase, significantly greater reductions in TJC and SJC were achieved with OTEZLA 30 mg BID vs placebo at week 16 (TJC: -42.9% vs -7%, respectively; SJC: -50% vs -16.7%, respectively; P < 0.0001 for both).2*

Significantly more patients on OTEZLA achieved an ACR20 response vs placebo1,3

  • At week 16, more than twice as many patients treated with OTEZLA 30 mg BID achieved the primary endpoint of modified ACR20 vs placebo (64/161 [39.8%] vs 32/165 [19.4%]; P = 0.0001)
  • ACR20 response rates were sustained for up to 4 years in patients receiving OTEZLA 30mg BID

*PALACE 1-3 pooled analysis. Per-protocol population, LOCF.

PALACE 1 study. Per-protocol population, LOCF.

PALACE 1 study. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24.

ACR, American College of Rheumatology; BID, twice daily; LOCF, last observation carried forward; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy; SJC, swollen joint count; TJC, tender joint count.

References:

  1. Kavanaugh A, Chen P, Fang L, et al. Durability of apremilast response in patients with psoriatic arthritis: long-term (208-week) results from the PALACE 1 trial. Ann Rheum Dis. 2017;76 (suppl 2): Abstract SAT0436.
  2. Cutolo M, Mease PJ, Gladman D, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in tender and swollen joint counts in patients with psoriatic arthritis: results from three phase 3, randomized, controlled trials. Presented at: the 2013 ACR/ARHP Annual Meeting; October 26-30, 2013; San Diego, CA. Abstract 317.
  3. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020-1026.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 51 Countries
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Singapore

  • Kuwait

  • Taiwan

  • UAE

  • Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil